home / stock / sabs / sabs articles
SIOUX FALLS, S.D., Oct. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a nove...
Funding to support clinical advancement of SAB-142, a potential disease-modifying treatment Financing led by RA Capital Management, with participa...
SAB Biotherapeutics (NASDAQ: SABS) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferr...
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc. Company Name:
SABS Stock Symbol:
NASDAQ Market:
SAB Biotherapeutics Inc. Website:
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is one of today's top gainers. The company's shares have moved 0% on the day to $2.77. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advance...
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB...
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progre...